DDInter245 DDInter1747
Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Brompheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tripelennamine
Brompheniramine {u} (Compound) resembles {v} (Compound) Captodiame
Brompheniramine {u} (Compound) resembles {v} (Compound) Pheniramine
Brompheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofedanol
Brompheniramine {u} (Compound) binds {v} (Gene) CYP3A4
Brompheniramine {u} (Compound) downregulates {v} (Gene) IER3
Brompheniramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyaluronidase
Brompheniramine {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Brompheniramine {u} may lead to a major life threatening interaction when taken with {v} Zonisamide
Brompheniramine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carbinoxamine
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Brompheniramine (Compound) resembles Captodiame (Compound)
Brompheniramine (Compound) resembles Pheniramine (Compound)
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Brompheniramine (Compound) binds CYP3A4 (Gene)
Brompheniramine (Compound) downregulates IER3 (Gene)
Brompheniramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Brompheniramine may lead to a major life threatening interaction when taken with Potassium chloride
Brompheniramine may lead to a major life threatening interaction when taken with Zonisamide
Brompheniramine (Compound) resembles Carbinoxamine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine